Biochemical and Biophysical Research Communications 379 (2009) 127–132

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

Efficient osteoblast differentiation from mouse bone marrow stromal cells with polylysin-modified adenovirus vectors

Katsuhisa Tashiro [a,b], Asami Kondo [a], Kenji Kawabata [a], Haruna Sakurai [a,b], Fuminori Sakurai [a], Koichi Yamanishi [b,c], Takao Hayakawa [d,e], Hiroyuki Mizuguchi [a,b,*]

[a] Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
[b] Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
[c] National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
[d] Pharmaceutics and Medical Devices Agency, 3-3-2, Kasumigaseki, Chiyoda-Ku, Tokyo 100-0013, Japan
[e] Pharmaceutical Research and Technology Institute, Kinki University, 3-4-1. Kowakae, Higashi-Osaka, Osaka 577-8502, Japan

ARTICLE INFO

Article history:
Received 2 December 2008
Available online 25 December 2008

Keywords:
Fiber-modified adenovirus vectors
Bone marrow stromal cells
Osteoblasts

ABSTRACT

Bone marrow stromal cells (BMSCs) are expected to be a source for tissue regeneration because they can differentiate into multiple cell types. Establishment of efficient gene transfer systems for BMSCs is essential for their application to regenerative medicine. In this study, we compared the transduction efficiency in mouse primary BMSCs by using fiber-modified adenovirus (Ad) vectors, and demonstrated that AdK7, which harbors a polylysin (K7) peptide in the C-terminus of the fiber knob, could efficiently express a transgene in BMSCs. Notably, AdK7 robustly drove transgene expression in more than 90% of the BMSCs at 3,000 vector particles/cell. Furthermore, we showed that *in vitro* and *in vivo* osteogenic potential of BMSCs was dramatically promoted by the transduction of Runx2 gene using AdK7. These results indicate that this transduction system could be a powerful tool for therapeutic applications based on BMSCs.

Because bone marrow stromal cells (BMSCs) containing mesenchymal stem cells (MSCs) can be easily isolated from adult tissues and efficiently expanded *in vitro*, and can differentiate into multiple cell types [1,2], BMSCs are expected to be an ideal source of cells for the regeneration of tissues. However, it is difficult to obtain a large amount of pure differentiated cells from BMSCs because of their low differentiation efficiency. The cell transition from stem cells to lineage-committed cells involves many transcription factors that promote or suppress cellular differentiation [3]. Thus, to develop an efficient method for differentiating from BMSCs into specialized cells, we planned to combine the transduction of a functional gene, which promotes cellular differentiation, with stimulation by chemical reagents. To do this procedure, it is essential to develop efficient transduction systems for BMSCs.

Among the various types of gene delivery vectors, adenovirus (Ad) vectors have been widely used for gene transfer studies, since they can achieve high transduction efficiency and transduce both dividing and non-dividing cells [4]. Although Ad vector-mediated transduction into BMSCs has been performed, the transduction efficiency was found to be lower than those of many other cell lines [5,6]. This is due to the low levels of coxsackievirus and adenovirus receptor (CAR), which mediates adenovirus entry, on the cell surface [5,6]. To overcome this problem, we and others have generated several types of fiber-modified Ad vectors, which mediate efficient gene transduction into the cells expressing very low levels of CAR [7,8]. Transduction efficiency was improved in various types of the cells by the insertion of Arg-Gly-Asp (RGD) peptide or 7-tandem lysine residues (KKKKKKK: K7) peptide, which targets αv integrins or heparan sulfates, respectively, on the cell surface, into the fiber knob of the Ad vector [7,8]. In particular, we previously reported that polylysin-modified Ad vector (AdK7) is the most suitable vector for transduction into human bone marrow-derived MSCs (hMSCs) [9].

In this study, we initially investigated the transduction efficiency of mouse primary BMSCs by using fiber-modified Ad vectors. We next examined whether the osteogenic potential of BMSCs was promoted by using Ad vector-mediated transduction of a runt-related transcription factor 2 (Runx2) gene, which is known as a master gene for osteoblastogenesis [10,11].

Materials and methods

Ad vectors. Ad vectors were constructed using an improved *in vitro* ligation method [12,13]. The CA (cytomegalovirus (CMV) enhancer/β-actin promoter) promoter [14]-driven β-galactosidase

* Corresponding author. Address: Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. Fax: +81 72 641 9816.
E-mail address: mizuguch@nibio.go.jp (H. Mizuguchi).

0006-291X/$ - see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2008.12.055

(LacZ)-expressing plasmid, pHMCA-LacZ [15], was digested with I-*Ceu*I/PI-*Sce*I and inserted into I-*Ceu*I/PI-*Sce*I-digested pAdHM15-RGD [16] or pAdHM41-K7 (C) [8], resulting in pAdRGD-CA-LacZ, pAdK7-CA-LacZ, respectively. The CMV or the human elongation factor (EF)-1α promoter-driven LacZ-expressing plasmid, pHMCMV-LacZ [15] or pHMEF-LacZ [15], respectively, was also digested with I-*Ceu*I/PI-*Sce*I and ligated into I-*Ceu*I/PI-*Sce*I-digested-pAdHM41-K7 (C), resulting in pAdK7-CMV-LacZ or pAdK7-EF-LacZ, respectively. The CA promoter-driven mouse Runx2-expressing plasmid, pHMCA-Runx2, was generated by inserting a mouse Runx2 cDNA, which is derived from pCMV-Runx2 (a kind gift from Dr. S. Takeda, Tokyo Medical and Dental University, Tokyo, Japan) [17], into pHMCA5. pHMCA-Runx2 was also digested with I-*Ceu*I/PI-*Sce*I, and inserted with pAdHM4 [12] or pAdHM41-K7 (C), resulting in pAd-CA-Runx2 or pAdK7-CA-Runx2, respectively. Ad vectors (Ad-CA-LacZ, AdRGD-CA-LacZ, AdK7-CA-LacZ, AdK7-CMV-LacZ, AdK7-EF-LacZ, Ad-CA-Runx2, and AdK7-CA-Runx2) were generated and purified as described previously [18]. Determination of virus particle (VP) and biological titer were determined using by a spectrophotometrical method [19] and by means of an Adeno-X Rapid Titer Kit (Clontech, Palo Alto, CA), respectively. The ratio of the biological-to-particle titer was 1:14 for Ad-CA-LacZ, 1:35 for AdRGD-CA-LacZ, 1:42 for AdK7-CA-LacZ, 1:25 for AdK7-CMV-LacZ, 1:32 for AdK7-EF-LacZ, 1:17 for Ad-CA-Runx2, and 1:28 for AdK7-CA-Runx2.

Mouse primary BMSCs. Primary BMSCs were harvested from female C57BL/6 mice (8 weeks; Nippon SLC, Shizuoka, Japan) as below. Femora and tibias were isolated and placed in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO)/20% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin. Bone marrow was obtained by flushing these bones, and cells recovered from the bones of one animal were then seeded into a 150 mm tissue culture plate. Medium was changed every 2 days to remove non-adherent cells, and adherent cells were cultured until reaching confluence. At confluence, BMSCs were passaged after digestion with 0.25% trypsin/1 mM EDTA. BMSCs (passage 4–12) were subsequently used for further analysis.

LacZ assay. BMSCs (1×10^4 cells) were plated in 24-well plates. The next day, they were transduced with the indicated doses of Ad vectors for 1.5 hr. Two days later, X-gal staining and β-gal luminescence assays were performed as described previously [18].

Osteoblasts differentiation. BMSCs (1×10^4 cells) were plated in 24-well plates. Cells were transduced with 3000 VP/cell of Ad vector for 1.5 hr. After aspirating the viral solution, osteogenic differentiation medium, consisting of growth medium (DMEM/20% FBS) containing 50 μg/mL ascorbic acid 2-phosphate (Sigma), 5 mM β-glycerophosphate (Sigma), and 100 nM dexamethasone (Wako, Osaka, Japan), was added. The medium was replaced every 3 days.

von Kossa staining, calcium quantitation. Cells were fixed with 4% paraformaldehyde/phosphate-buffered saline (PBS) and stained with $AgNO_3$ by the von Kossa method. To measure calcium deposition, cells were washed twice with PBS and decalcified with 0.5 M acetic acid, and cell culture plates were rotated overnight at room temperature (R/T). Insoluble material was removed by centrifugation. The supernatants were then assayed for calcium with the calcium C-test Wako kit (Wako). DNA in pellets was extracted using the DNeasy tissue kit (Qiagen), and calcium content was then normalized to DNA.

ALP assay. Cells were lysed in 10 mM Tris–HCl (pH 7.5) containing 1 mM $MgCl_2$ and 0.1% Triton X-100, and the lysates were then used for assay. Alkaline phosphatase (ALP) activity was measured using the LabAssay ALP kit (Wako) according to the manufacturer's instructions. The protein concentration of the lysates was determined using a Bio-Rad assay kit (Bio-Rad laboratories, Hercules, CA), and ALP activity was then normalized by protein concentration.

RT-PCR. RT-PCR was performed as described previously [18]. The sequences of primers were as follows: Runx2(F), 5′-CCT CTG ACT TCT GCC TCT GG-3′; Runx2(R), 5′-CAG CGT CAA CAC CAT CAT TC-3′; osterix(F), 5′- CTT AAC CCA GCT CCC TAC CC-3′; osterix(R), 5′- TGT GAA TGG GCT TCT TCC TC-3′; bone sialoprotein(F), 5′- AAA GTG AAG GAA AGC GAC GA-3′; bone sialoprotein(R), 5′-GTT CCT TCT GCA CCT GCT TC-3′; osteocalcin(F), 5′-GCG CTC TGT CTC TCT GAC CT -3′; osteocalcin(R), 5′-TTT GTA GGC GGT CTT CAA GC-3′; collagen Iα1(F), 5′-CAC CCT CAA GAG CCT GAG TC-3′; collagen Iα1 (R), 5′-GCT ACG CTG TTC TTG CAG TG-3′, GAPDH(F), 5′-ACC ACA GTC CAT GCC ATC AC-3′; GAPDH(R), 5′-TCC ACC ACC CTG TTG CTG TA-3′.

Western blotting. Western blotting was performed as described previously [18]. Briefly, lysates (20 μg) were subjected to 12.5% polyacrylamide gel and were transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA). After blocking with Immunoblock (DS Pharma Biomedical, Osaka, Japan) at R/T for 1 hr, the membrane was exposed to rabbit anti-Runx2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 4 °C overnight, followed by horseradish peroxidase-conjugated secondary antibody at R/T for 1 hr. The band was visualized by ECL Plus Western blotting detection reagents (Amersham Bioscience, Piscataway, NJ) and the signals were read using a LAS-3000 imaging system (FUJIFILM, Tokyo, Japan). All blots were stripped and reblotted with antibody against β-actin (Sigma) for normalization.

In vivo heterotopic bone formation. BMSCs (2×10^6 cells, passage 8–9) were transduced with AdK7-CA-LacZ, AdK7-CA-Runx2, or Ad-CA-Runx2, at 3000 VP/cells for 1.5 hr. The next day, cells were collected by trypsin, and resuspended in 150 μl of PBS, and then injected into the hind limb biceps muscle of nude mice (Nippon SLC) (2animal/ group). At 4–5 weeks after injection, mice were anesthetized by isofluorane and bone formation was analyzed with a microcomputed tomography (microCT) system (eXplore Locus CT System; GE Healthcare, London, ON, Canada). Both an X-ray image and a three-dimensional reconstitution image were obtained by using the microCT system.

Results

Optimization of transduction efficiency in BMSCs by using various types of Ad vectors

To optimize Ad vectors for transduction into BMSCs, we prepared three LacZ-expressing Ad vectors, Ad-CA-LacZ, AdRGD-CA-LacZ, and AdK7-CA-LacZ. We investigated the transduction efficiency of these Ad vectors in BMSCs at the indicated vector dose. X-gal staining showed that LacZ-positive cells were less than 10% even at a dose of 3000 vector particles (VP)/cell in Ad-CA-LacZ (Fig. 1A). On the other hand, more than 90% of the cells expressed LacZ at the same dose in AdK7-CA-LacZ. A luminescence assay revealed that, at 3000 VP/cell, the LacZ expression level in the cells transduced with AdRGD-CA-LacZ or AdK7-CA-LacZ was increased by about 5- or 50-fold, respectively, in comparison with that in the cells transduced with Ad-CA-LacZ (Fig. 1B). These results were quite similar to those of our previous report, in which efficient transduction in hMSCs was achieved by using AdK7 [9], and our data clearly demonstrated that AdK7 is a suitable vector for transduction into both mouse BMSCs and hMSCs.

We and others reported that the choice of promoters is important for transduction efficiency, especially in immature cells [15,18,20,21]. Thus, we examined the transduction efficiency by comparing the promoter activities in BMSCs. In addition to the CA promoter, we prepared LacZ-expressing AdK7 under the control of the CMV promoter or the EF-1α promoter (AdK7-CMV-LacZ or AdK7-EF-LacZ, respectively). A luminescent assay showed that the CA promoter represented the highest transgene expression



Fig. 1. Gene transduction efficiency in mouse primary BMSCs by various types of Ad vectors. Mouse BMSCs were transduced with the indicated doses of LacZ-expressing Ad vectors. Two days later, (A) X-gal staining and (B) luminescence assay were performed. Similar results of X-gal staining were obtained in three independent experiments. Scale bar indicates 200 μm. (C) Optimization of promoter activity in BMSCs using LacZ-expressing AdK7. BMSCs were transduced with the indicated dose of each Ad vector, and LacZ expression in the cells was measured. The data are expressed as mean ± S.D. ($n = 3$). * $p < 0.01$.

among the three types of the promoters (Fig. 1C). These results demonstrate that AdK7 containing the CA promoter is the most effective at attaining high transduction efficiency in mouse BMSCs.

We also investigated the cytotoxicity in BMSCs transduced with AdK7-CA-LacZ. Almost no difference in cell number between non-transduced cells and AdK7-CA-LacZ-transduced cells was observed on day 2 after transduction (data not shown), indicating that AdK7 is an excellent vector with high transduction activity and low cytotoxicity in BMSCs.

Efficient osteoblast differentiation in vitro and in vivo by fiber-modified Ad vectors

Because an efficient method for transduction into BMSCs could be established by using AdK7 containing the CA promoter, we expected that efficient differentiation into specialized cells from BMSCs might be achieved by using this Ad vector. To test this, we generated mouse Runx2-expressing Ad vectors, AdK7-CA-Runx2 and Ad-CA-Runx2, because a Runx2 gene is both necessary and sufficient for mesenchymal cell differentiation towards osteoblast lineage [3]. Western blot analysis showed that Runx2 protein levels in AdK7-CA-Runx2-transduced cells were quite higher than those in non-, AdK7-CA-LacZ-, or Ad-CA-Runx2-transduced cells (Fig. 2).



Fig. 2. Runx2 expression in Ad vector-transduced BMSCs. Cell lysates were isolated from BMSCs 2 days after the transduction, and Western blotting was performed.

We next assessed osteoblast differentiation by measuring alkaline phosphatase (ALP) activity, which is a marker of early osteoblast differentiation. After transduction with Ad vector, BMSCs were cultured in osteogenic differentiation medium for the indicated number of days. As shown in Fig. 3A, the ALP activity levels in AdK7-CA-Runx2-transduced cells were extremely increased in comparison with control cells. Notably, AdK7-CA-Runx2 mediated approximately 50-fold higher ALP activity than non-transduction or AdK7-CA-LacZ on day 5 after transduction. These results indicated that early osteoblast differentiation of BMSC was facilitated by AdK7-CA-Runx2. Because mature osteoblasts are known to be specialized in the production of extracellular matrix and the mineralization [22], we next examined the matrix mineralization in BMSCs. von Kossa staining revealed that matrix mineralization in AdK7-CA-Runx2-transduced cells was dramatically increased in comparison with non-, AdK7-CA-LacZ, or Ad-CA-Runx2-transduced cells (Fig. 3B, left). Furthermore, we observed a significant elevation of calcium deposition in AdK7-CA-Runx2-transduced cells even on day 5 after transduction, while neither non-transduced cells nor AdK7-CA-LacZ-transduced cells showed mineralization until day 15 (Fig. 3B, right). Ad-CA-Runx2 mediated slightly higher levels of calcium deposition than non-transduced or AdK7-CA-LacZ-transduced cells, but significantly lower levels than AdK7-CA-Runx2-transduced cells. Additionally, we found that the expression levels of marker genes characteristic of osteoblast differentiation, such as Runx2, osterix, bone sialoprotein, osteocalcin, and type I collagen, were also increased in AdK7-CA-Runx2-transduced cells (Fig. 3C). These results demonstrated that a conventional method using only osteogenic differentiation medium is



Fig. 3. Promotion of *in vitro* osteoblastic differentiation in AdK7-CA-Runx2-transduced BMSC. After transduction with each Ad vector at 3000 VP/cell for 1.5 hr, BMSCs were cultured for the indicated number of days. (A) ALP activity, (B, left) matrix mineralization, and (B, right) calcium deposition in the cells was determined. The data are expressed as mean ± S.D. ($n = 3$). * $p < 0.01$ as compared with non-, AdK7-CA-LacZ-, or Ad-CA-Runx2-transduced cells. (C) RT-PCR was performed using primers for Runx2, osterix, bone sialoprotein, osteocalcin, collagen type I, and GAPDH. Lane 0: non-treated BMSCs; lanes 1, 5, 9, and 13: BMSCs with osteogenic supplements (OS); lanes 2, 6, 10, and 14: BMSCs with OS plus AdK7-CA-LacZ; lanes 3, 7, 11, and 15: BMSCs with OS plus AdK7-CA-Runx2; lanes 4, 8, 12, and 16: BMSCs with OS plus Ad-CA-Runx2.

not enough for efficient osteoblast differentiation, and that, by efficient Runx2 transduction using AdK7, osteoblastogenesis of BMSCs could be dramatically accelerated *in vitro*.

Finally, to examine whether the increased levels of Runx2 expression in BMSCs could enhance the osteogenic potential of BMSC *in vivo*, BMSCs transduced with each Ad vector were injected into the hind limb biceps muscle of nude mice. Microcomputed tomography analysis revealed that no bone formation was observed in non-, AdK7-CA-LacZ-, or Ad-CA-Runx2-transduced cells, while new bone was detected in mice injected with AdK7-CA-Runx2-transduced cells (Fig. 4), indicating that AdK7-CA-Runx2-transduced BMSCs efficiently differentiated into mature osteoblasts *in vivo*. These results clearly showed that AdK7-CA-Runx2 could facilitate the osteogenic potential of BMSCs both *in vitro* and *in vivo*.

Discussion

Because genetic manipulation is considered to be a powerful tool to promote cellular differentiation, it is necessary to establish efficient methods for transduction into BMSCs. Many researchers have reported that transduction efficiency of rat or human MSC was increased by using fiber-modified Ad vectors, such as AdRGD or Ad vectors containing Ad35 fiber knob and



Fig. 4. *In vivo* ectopic bone formation of mouse BMSCs by AdK7-mediated Runx2 gene transduction. BMSCs were transduced with indicated Ad vectors at 3000 VP/cell. On the following day, cells were injected into the hind limb biceps muscle of nude mice. Four weeks later, bone formation was analyzed by the microCT system. Similar results were obtained in two independent experiments. Upper: X-ray images; lower: 3D reconstitution images.

shaft (AdF35) [23–25]. In this study, we demonstrated that AdK7 could express a transgene in BMSCs more efficiently than conventional Ad vector or AdRGD (Fig. 1A and B). Similarly, we have previously shown that the highest transduction efficiency in hMSC could be achieved by using AdK7, but not AdRGD or AdF35 [9]. Therefore, our data indicate that AdK7 is the most appropriate vector for various mesenchymal cells. We also found that the CA promoter showed higher gene expression in BMSCs than did the CMV or EF-1α promoter (Fig. 1C). This appears to be due to the potent activity of the CA promoter in immature cells [18,20]. Hence, we conclude that AdK7 containing the CA promoter is the most suitable vector for transduction into BMSCs.

We demonstrated that osteoblastogenesis of BMSCs was dramatically promoted by using AdK7-mediated Runx2 transduction (Figs. 3 and 4). This is the first study to report the usefulness of AdK7 in the field of stem cell differentiation. Runx2 is known to regulate osteoblastogenesis by controlling the expression of multiple osteoblast marker genes [10]. Because Runx2 protein and mRNA were highly expressed for more than 20 days in AdK7-CA-Runx2-trasduced cells (Figs. 2 and 3C), the expression of marker genes and ALP activity would be increased and would thereby enhance both *in vitro* and *in vivo* osteogenic ability. On the other hand, osteoblast differentiation could not be facilitated by AdK7-CA-Runx2 when osteogenic supplements were removed (data not shown), suggesting that osteogenic supplements were required for matrix mineralization, although differentiation efficiency was low when using only osteogenic supplements. Thus, efficient osteoblast differentiation of BMSCs would be achieved by the synergistic effect of both osteogenic supplements and efficient Runx2 transduction.

Unlike the case with AdK7-CA-Runx2, almost no osteoblast differentiation was seen in Ad-CA-Runx2-transduced cells. However, several groups reported that the osteogenic potential of MSCs was enhanced by Runx2 transduction using the conventional Ad vectors [26,27]. This difference would be attributable to the difference in transduction efficiency in BMSCs using the conventional Ad vector, because they showed that approximately 30–40% of the cells expressed transgenes by conventional Ad vector at 250–500 infectious units (ifu)/cell. Although we could not obtain high transduction efficiency using the conventional Ad vector, we showed that more than 90% of the cells were transduced by using AdK7-CA-LacZ at only 71 ifu/cell (3000 VP/cell) (Fig. 1A), without any decrease in viability (data not shown). Our results indicate that vector doses can be reduced by using AdK7, leading to a decrease in cytotoxicity to the cells. Therefore, AdK7, but not other fiber-modified Ad vectors or conventional Ad vectors, would contribute to safe regenerative medicine procedures.

In summary, we succeeded in developing efficient methods both for transducing mouse BMSCs and differentiating osteoblasts from BMSCs. Recently, many researchers have reported that mesenchymal stem/stromal cells could be isolated from adipose or placental tissues [28,29]. Because these mesenchymal cells are shown to possess mostly the same properties as BMSCs, AdK7 could probably be applied to these cells. Thus, our transduction methods can be a valuable tool for therapeutic applications based on adult mesenchymal stem/stromal cells.

Acknowledgments

We thank Dr. J. Miyazaki and Dr. S. Takeda for providing the CA promoter and the mouse Runx2 cDNA, respectively. This work was supported by grants from the Ministry of Health, Labor, and Welfare of Japan. K.T. is the Research Fellow of the Japan Society for the Promotion of Science.

References

[1] M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, D.R. Marshak, Multilineage potential of adult human mesenchymal stem cells, Science 284 (1999) 143–147.
[2] M.F. Pittenger, B.J. Martin, Mesenchymal stem cells and their potential as cardiac therapeutics, Circ. Res. 95 (2004) 9–20.

[3] P.J. Marie, Transcription factors controlling osteoblastogenesis, Arch. Biochem. Biophys. 473 (2008) 98–105.
[4] K. Benihoud, P. Yeh, M. Perricaudet, Adenovirus vectors for gene delivery, Curr. Opin. Biotechnol. 10 (1999) 440–447.
[5] P.A. Conget, J.J. Minguell, Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells, Exp. Hematol. 28 (2000) 382–390.
[6] S.C. Hung, C.Y. Lu, S.K. Shyue, H.C. Liu, L.L. Ho, Lineage differentiation-associated loss of adenoviral susceptibility and coxsackie-adenovirus receptor expression in human mesenchymal stem cells, Stem cells 22 (2004) 1321–1329.
[7] I. Dmitriev, V. Krasnykh, C.R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, D.T. Curiel, An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism, J. Virol. 72 (1998) 9706–9713.
[8] N. Koizumi, H. Mizuguchi, N. Utoguchi, Y. Watanabe, T. Hayakawa, Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob, J. Gene Med. 5 (2003) 267–276.
[9] H. Mizuguchi, T. Sasaki, K. Kawabata, F. Sakurai, T. Hayakawa, Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells, Biochem. Biophys. Res. Commun. 332 (2005) 1101–1106.
[10] P. Ducy, R. Zhang, V. Geoffroy, A.L. Ridall, G. Karsenty, Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation, Cell 89 (1997) 747–754.
[11] T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto, Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts, Cell 89 (1997) 755–764.
[12] H. Mizuguchi, M.A. Kay, Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method, Hum. Gene Ther. 9 (1998) 2577–2583.
[13] H. Mizuguchi, M.A. Kay, A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors, Hum. Gene Ther. 10 (1999) 2013–2017.
[14] H. Niwa, K. Yamamura, J. Miyazaki, Efficient selection for high-expression transfectants with a novel eukaryotic vector, Gene 108 (1991) 193–199.
[15] K. Kawabata, F. Sakurai, T. Yamaguchi, T. Hayakawa, H. Mizuguchi, Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors, Mol. Ther. 12 (2005) 547–554.
[16] H. Mizuguchi, N. Koizumi, T. Hosono, N. Utoguchi, Y. Watanabe, M.A. Kay, T. Hayakawa, A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob, Gene Ther. 8 (2001) 730–735.
[17] S. Takeda, J.P. Bonnamy, M.J. Owen, P. Ducy, G. Karsenty, Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice, Genes Dev. 15 (2001) 467–481.
[18] K. Tashiro, K. Kawabata, H. Sakurai, S. Kurachi, F. Sakurai, K. Yamanishi, H. Mizuguchi, Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation, J. Gene Med. 10 (2008) 498–507.
[19] J.V. Maizel Jr., D.O. White, M.D. Scharff, The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12, Virology 36 (1968) 115–125.
[20] F. Sakurai, K. Kawabata, T. Yamaguchi, T. Hayakawa, H. Mizuguchi, Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities, Gene Ther. 12 (2005) 1424–1433.
[21] S. Chung, T. Andersson, K.C. Sonntag, L. Bjorklund, O. Isacson, K.S. Kim, Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines, Stem Cells 20 (2002) 139–145.
[22] H.C. Blair, M. Zaidi, P.H. Schlesinger, Mechanisms balancing skeletal matrix synthesis and degradation, Biochem. J. 364 (2002) 329–341.
[23] E.A. Olmsted-Davis, Z. Gugala, F.H. Gannon, P. Yotnda, R.E. McAlhany, R.W. Lindsey, A.R. Davis, Use of a chimeric adenovirus vector enhances BMP2 production and bone formation, Hum. Gene Ther. 13 (2002) 1337–1347.
[24] S. Knaan-Shanzer, M.J. van de Watering, I. van der Velde, M.A. Goncalves, D. Valerio, A.A. de Vries, Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells, Stem cells 23 (2005) 1598–1607.
[25] H. Tsuda, T. Wada, T. Yamashita, H. Hamada, Enhanced osteoinduction by mesenchymal stem cells transfected with a fiber-mutant adenoviral BMP2 gene, J. Gene Med. 7 (2005) 1322–1334.
[26] Z. Zhao, M. Zhao, G. Xiao, R.T. Franceschi, Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo, Mol. Ther. 12 (2005) 247–253.
[27] X. Zhang, M. Yang, L. Lin, P. Chen, K.T. Ma, C.Y. Zhou, Y.F. Ao, Runx2 overexpression enhances osteoblastic differentiation and mineralization in adipose–derived stem cells in vitro and in vivo, Calcif. Tissue Int. 79 (2006) 169–178.
[28] Y. Fukuchi, H. Nakajima, D. Sugiyama, I. Hirose, T. Kitamura, K. Tsuji, Human placenta-derived cells have mesenchymal stem/progenitor cell potential, Stem Cells 22 (2004) 649–658.
[29] J.M. Gimble, A.J. Katz, B.A. Bunnell, Adipose-derived stem cells for regenerative medicine, Circ. Res. 100 (2007) 1249–1260.